Dr Shaun Fleming
Dr Shaun Fleming is a clinical and laboratory haematologist with a particular interest in the management of Acute Leukaemias, in particular Acute Lymphoblastic Leukaemia, allogeneic stem cell transplantation for leukaemia and immunotherapies in acute leukaemia including CART therapy. His focus is on providing access to high quality care in Acute Leukaemia and the investigation of novel therapies to improve the outcome of leukaemia patients.
At the conclusion of his physician and haematology training he completed a fellowship in Acute Leukaemia at the Alfred where his research interests were focused on the application of machine learning to the prognostication of acute myeloid leukaemia and the application of measurable residual disease testing on novel markers following allogeneic stem cell transplantation.
Shaun leads the Acute Lymphoblastic Leukaemia program at the Alfred and is principal investigator on clinical trials in acute leukaemia and cellular therapies. He is the chief investigator on the national Australasian Leukaemia and Lymphoma Group ALL08 study of the application of novel therapies to adults with ALL and is currently leading a registry based study of measurable residual disease directed therapies in older adults with ALL.
In addition to his clinical and clinical trial roles Shaun leads investigation into the application of machine learning and data science into haematology and works within the diagnostic laboratory where his focus is on flow cytometry and MRD testing. He supervises the registrar training program in clinical haematology at the Alfred.